Neoadjuvant chemotherapy and radiation therapy in locally advanced non-small cell lung cancer [NSCLC]
Ain-Shams Medical Journal. 1995; 46 (1-2-3): 99-111
em Inglês
| IMEMR
| ID: emr-36051
ABSTRACT
This study included 12 patients with locally advanced histologically proven non-small cell carcinoma of the lung who presented to Kasr El-Aini Center of Oncology and Nuclear Medicine [NEMROCK] from the first of August to the first of December, 1993. Patients received 3 cycles of neoadjuvant Carboplatin [300 mg/m [2]] I.V. bolus on day 1] and VP16 [120 mg/m [2] I.V. infusion over 30 minutes day 1 to day 3] followed by radiation therapy [45 Gy to the primary and mediastinum followed by 15 - 20 Gy boost to the primary]. 92% of cases were males with a mean age of 52 +/- 15 years, history of cigarette smoking has been observed in 58.4%. Adenocarcinoma was the most frequent pathological type [50%] followed by squamous cell [41.6%] and large cell carcinoma [8.4%]. Eleven cases were considered evaluable for assessment of treatment response with a median follow up of 9 months. The overall response rate was 64%. One case showed complete response [CR], 6 showed partial response [PR] and were considered responders while 4 showed no change [NC] and considered non-responders. Squamous cell carcinoma was statistically better than adenocarcinoma [80% of the former showed PR versus 33% of the latter]. In this study, the responders showed a better total actuarial survival than the non-responders
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Carcinoma de Células Escamosas
/
Adenocarcinoma
/
Fumar
/
Taxa de Sobrevida
/
Seguimentos
/
Quimioterapia Adjuvante
/
Carcinoma Pulmonar de Células não Pequenas
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Ain-Shams Med. J.
Ano de publicação:
1995
Similares
MEDLINE
...
LILACS
LIS